Importantly, we indicated that KDM6A enhanced the efficacy of lenvatinib treatment in HCC and proposed that it may be a prognostic biomarker to determine the effectiveness of lenvatinib therapy for HCC. This evidence concerns the gene KDM6A and hepatocellular carcinoma.